How can we optimize the diagnostic and therapeutic approach to Staphylococcus aureus bacteremia? Expert opinion-based recommendations

2026/07/07 by Mario Fernández-Ruiz, Belén Gutiérrez-Gutiérrez, Francesc Escrihuela-Vidal +7
Biochemistry, Genetics and Molecular Biology · Medicine · #Antibiotics #Antimicrobial Resistance in Staphylococcus #Bacterial Identification and Susceptibility Testing #MEDLINE #Ocular Infections and Treatments #Staphylococcal infections #Staphylococcus aureus #Therapeutic approach

paper · doi:10.1016/j.eimc.2026.503253

openalex publication_date 2026/07/07 · crossref created 2026/07/07 · openalex created_date 2026/07/08 · crossref deposited 2026/08/04 · crossref indexed 2026/08/04 · openalex updated_date 2026/08/06 · crossref issued 2026/11/01 · crossref published 2026/11/01 · crossref published-print 2026/11/01

Citations

• Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial
• Follow-up blood cultures in Staphylococcus aureus bacteremia: a probability-based optimization
• Management of Staphylococcus aureus Bacteremia
• Cefazolin vs. antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis
• Is Time to Positivity in Staphylococcus aureus Bacteremia a Harbinger of Endocarditis?
• Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials
• Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial